221 related articles for article (PubMed ID: 27124583)
1. CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Drachsler M; Kleber S; Mateos A; Volk K; Mohr N; Chen S; Cirovic B; Tüttenberg J; Gieffers C; Sykora J; Wirtz CR; Mueller W; Synowitz M; Martin-Villalba A
Cell Death Dis; 2016 Apr; 7(4):e2209. PubMed ID: 27124583
[TBL] [Abstract][Full Text] [Related]
2. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD
Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041
[TBL] [Abstract][Full Text] [Related]
3. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
4. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Yu F; Li G; Gao J; Sun Y; Liu P; Gao H; Li P; Lei T; Chen Y; Cheng Y; Zhai X; Sayari AJ; Huang H; Mu Q
Cell Prolif; 2016 Apr; 49(2):195-206. PubMed ID: 26923184
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Bhawe K; Felty Q; Yoo C; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Roy D
Mol Neurobiol; 2020 Sep; 57(9):3827-3845. PubMed ID: 32594352
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
Cheng ZX; Yin WB; Wang ZY
Int J Mol Med; 2017 Nov; 40(5):1307-1314. PubMed ID: 28901390
[TBL] [Abstract][Full Text] [Related]
7. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
8. RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.
Yeom SY; Nam DH; Park C
Mol Cancer Ther; 2014 Dec; 13(12):3049-61. PubMed ID: 25313011
[TBL] [Abstract][Full Text] [Related]
9. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
Koch K; Hartmann R; Schröter F; Suwala AK; Maciaczyk D; Krüger AC; Willbold D; Kahlert UD; Maciaczyk J
Oncotarget; 2016 Nov; 7(45):73414-73431. PubMed ID: 27705917
[TBL] [Abstract][Full Text] [Related]
12. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
13. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
14. FAT1 modulates EMT and stemness genes expression in hypoxic glioblastoma.
Srivastava C; Irshad K; Dikshit B; Chattopadhyay P; Sarkar C; Gupta DK; Sinha S; Chosdol K
Int J Cancer; 2018 Feb; 142(4):805-812. PubMed ID: 28994107
[TBL] [Abstract][Full Text] [Related]
15. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
17. HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.
Colamaio M; Tosti N; Puca F; Mari A; Gattordo R; Kuzay Y; Federico A; Pepe A; Sarnataro D; Ragozzino E; Raia M; Hirata H; Gemei M; Mimori K; Del Vecchio L; Battista S; Fusco A
Expert Opin Ther Targets; 2016 Oct; 20(10):1169-79. PubMed ID: 27486901
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.
Iwata R; Maruyama M; Ito T; Nakano Y; Kanemura Y; Koike T; Oe S; Yoshimura K; Nonaka M; Nomura S; Sugimoto T; Yamada H; Asai A
Med Mol Morphol; 2017 Dec; 50(4):211-219. PubMed ID: 28516286
[TBL] [Abstract][Full Text] [Related]
19. FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Chen C; Han G; Li Y; Yue Z; Wang L; Liu J
J Cell Biochem; 2019 Jan; 120(1):882-893. PubMed ID: 30216501
[TBL] [Abstract][Full Text] [Related]
20. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
